patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_386549 | REC_0015701 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.1 | 67 | male | 0 | 23 | 6.2 | 6 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:01.397794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699397 | REC_0015702 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.3 | 75 | female | 1 | 13 | 6.3 | 5 | sotorasib 960 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:36:01.398140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176055 | REC_0015703 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 3.8 | 62 | male | 1 | 36 | 3.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:36:01.398526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896085 | REC_0015704 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 16 | 14.6 | 69 | female | 1 | 15 | 6.3 | 2 | pembrolizumab 200 mg q3w | 20.7 | false | MSS | 2026-03-15T05:36:01.398939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798669 | REC_0015705 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.5 | 84 | female | 1 | 15 | 2.7 | 2 | osimertinib 80 mg daily | 22.7 | true | MSS | 2026-03-15T05:36:01.399583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787459 | REC_0015706 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5 | 69 | male | 1 | 17 | 6.2 | 4 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:36:01.400023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780093 | REC_0015707 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.6 | 70 | male | 1 | 24 | 6.5 | 5 | alectinib 600 mg BID | 6.7 | true | MSS | 2026-03-15T05:36:01.400713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974131 | REC_0015708 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.7 | 48 | female | 0 | 16 | 5.1 | 2 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:01.401157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596674 | REC_0015709 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.5 | 83 | male | 1 | 21 | 7.2 | 1 | osimertinib 80 mg daily | 23.3 | false | MSS | 2026-03-15T05:36:01.402229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450005 | REC_0015710 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.2 | 72 | female | 2 | 0 | 5.6 | 5 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:36:01.402698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614549 | REC_0015711 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.8 | 61 | male | 0 | 9 | 5.6 | 5 | entrectinib 600 mg daily | 7.3 | false | MSS | 2026-03-15T05:36:01.403158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528423 | REC_0015712 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.2 | 69 | female | 1 | 11 | 4.7 | 1 | sotorasib 960 mg daily | 6.1 | true | MSI-H | 2026-03-15T05:36:01.403601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933096 | REC_0015713 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 9.4 | 66 | male | 0 | 38 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:36:01.404046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101384 | REC_0015714 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.8 | 61 | female | 0 | 2 | 6.8 | 0 | pembrolizumab 200 mg q3w | 20.6 | false | MSS | 2026-03-15T05:36:01.404587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713565 | REC_0015715 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.3 | 79 | female | 2 | 10 | 5.6 | 2 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:01.405134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154323 | REC_0015716 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 7.8 | 67 | male | 1 | 22 | 5.4 | 5 | alectinib 600 mg BID | 6 | false | MSS | 2026-03-15T05:36:01.405524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217214 | REC_0015717 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 10.9 | 71 | male | 3 | 22 | 6.9 | 6 | pembrolizumab 200 mg q3w | 5.8 | false | MSI-H | 2026-03-15T05:36:01.405912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265390 | REC_0015718 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.8 | 71 | female | 2 | 18 | 6.2 | 5 | sotorasib 960 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:01.406522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665010 | REC_0015719 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 11.4 | 80 | female | 2 | 12 | 7.2 | 1 | entrectinib 600 mg daily | 26.5 | false | MSS | 2026-03-15T05:36:01.406917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445042 | REC_0015720 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9.2 | 60 | male | 0 | 18 | 3.6 | 7 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.407281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352395 | REC_0015721 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.9 | 64 | female | 0 | 37 | 6.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:36:01.407644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444795 | REC_0015722 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.6 | 66 | male | 0 | 5 | 7.4 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:01.408002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129808 | REC_0015723 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 15 | 11.4 | 66 | female | 1 | 0 | 6.7 | 1 | pembrolizumab 200 mg q3w | 24.2 | true | MSI-H | 2026-03-15T05:36:01.408443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967230 | REC_0015724 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.4 | 79 | female | 0 | 29 | 5.3 | 1 | osimertinib 80 mg daily | 15.7 | true | MSI-H | 2026-03-15T05:36:01.408903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841984 | REC_0015725 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.4 | 78 | female | 3 | 13 | 5.2 | 4 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:36:01.409342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147588 | REC_0015726 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 4.6 | 64 | female | 0 | 26 | 4.4 | 3 | alectinib 600 mg BID | 6.7 | true | MSS | 2026-03-15T05:36:01.409749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866954 | REC_0015727 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.8 | 62 | male | 0 | 21 | 6.8 | 4 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:01.410145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224924 | REC_0015728 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.8 | 68 | female | 1 | 13 | 6.5 | 4 | sotorasib 960 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:36:01.410522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566550 | REC_0015729 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 7.5 | 75 | female | 2 | 34 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:36:01.410941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696399 | REC_0015730 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 15.9 | 64 | female | 1 | 20 | 4.1 | 2 | alectinib 600 mg BID | 22.2 | false | MSS | 2026-03-15T05:36:01.411382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290605 | REC_0015731 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.3 | 55 | female | 1 | 20 | 7.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:36:01.411996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474337 | REC_0015732 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6 | 75 | male | 2 | 29 | 4.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:36:01.412601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121609 | REC_0015733 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 12.3 | 84 | female | 2 | 27 | 7.2 | 7 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:01.412995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940026 | REC_0015734 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.7 | 63 | male | 0 | 22 | 5.8 | 5 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:36:01.413402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734421 | REC_0015735 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.3 | 70 | female | 1 | 58 | 4 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:36:01.413774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350142 | REC_0015736 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 18.5 | 76 | female | 3 | 0 | 6 | 2 | entrectinib 600 mg daily | 20 | true | MSI-H | 2026-03-15T05:36:01.414126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158103 | REC_0015737 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.7 | 70 | female | 3 | 43 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:36:01.414452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844487 | REC_0015738 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7 | 64 | male | 0 | 79 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:01.414787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686541 | REC_0015739 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.2 | 70 | female | 1 | 12 | 4 | 2 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:36:01.415171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124489 | REC_0015740 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 68 | male | 1 | 19 | 6.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:36:01.415560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281226 | REC_0015741 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 7.6 | 77 | female | 2 | 11 | 4.4 | 1 | entrectinib 600 mg daily | 20.2 | false | MSS | 2026-03-15T05:36:01.415935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963266 | REC_0015742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.8 | 66 | female | 0 | 30 | 3.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:36:01.416740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405762 | REC_0015743 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.2 | 73 | male | 2 | 22 | 4.9 | 4 | sotorasib 960 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:36:01.417324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351834 | REC_0015744 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.7 | 66 | male | 0 | 14 | 7.1 | 8 | sotorasib 960 mg daily | 8.7 | false | MSS | 2026-03-15T05:36:01.417985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930090 | REC_0015745 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 8.1 | 77 | female | 2 | 21 | 7.7 | 1 | osimertinib 80 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:01.418461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239715 | REC_0015746 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.2 | 74 | female | 2 | 10 | 5.7 | 2 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:36:01.418884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515459 | REC_0015747 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 14.3 | 67 | male | 0 | 16 | 4.5 | 0 | osimertinib 80 mg daily | 36.5 | false | MSI-H | 2026-03-15T05:36:01.419317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226072 | REC_0015748 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 12 | 7.2 | 64 | female | 1 | 5 | 4.1 | 6 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:01.419712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421541 | REC_0015749 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 14.9 | 50 | male | 0 | 19 | 5.9 | 2 | pembrolizumab 200 mg q3w | 12 | false | MSI-H | 2026-03-15T05:36:01.420190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794822 | REC_0015750 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 6.6 | 75 | female | 1 | 8 | 5.6 | 1 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:01.420612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669278 | REC_0015751 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 15 | 8.7 | 62 | female | 1 | 14 | 7 | 0 | osimertinib 80 mg daily | 52.5 | false | MSS | 2026-03-15T05:36:01.421017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895493 | REC_0015752 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.8 | 71 | female | 1 | 34 | 5.2 | 6 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:01.421407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791825 | REC_0015753 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.2 | 50 | female | 0 | 35 | 4.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.9 | false | MSS | 2026-03-15T05:36:01.421793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322782 | REC_0015754 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.9 | 69 | female | 0 | 50 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 16 | true | MSS | 2026-03-15T05:36:01.423245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864507 | REC_0015755 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.7 | 68 | male | 0 | 18 | 4.3 | 4 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:01.423710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552153 | REC_0015756 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.7 | 73 | female | 2 | 31 | 5.6 | 5 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:01.424234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543404 | REC_0015757 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 13 | 58 | female | 0 | 17 | 6.1 | 0 | alectinib 600 mg BID | 38.1 | true | MSS | 2026-03-15T05:36:01.424913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545543 | REC_0015758 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 18 | 5.7 | 72 | male | 2 | 70 | 4.1 | 0 | pembrolizumab 200 mg q3w | 30.3 | false | MSS | 2026-03-15T05:36:01.425363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641642 | REC_0015759 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.3 | 74 | female | 2 | 16 | 3.8 | 7 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:01.425822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226192 | REC_0015760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.5 | 69 | female | 1 | 24 | 5.9 | 4 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:36:01.426268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677751 | REC_0015761 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.5 | 77 | female | 1 | 10 | 4.9 | 5 | entrectinib 600 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:36:01.426673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627037 | REC_0015762 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.8 | 71 | female | 3 | 4 | 5.3 | 5 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:01.427096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430683 | REC_0015763 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15.2 | 72 | female | 1 | 8 | 6.7 | 1 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:36:01.427485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685803 | REC_0015764 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.6 | 67 | female | 1 | 16 | 6.3 | 6 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:01.427878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256701 | REC_0015765 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 16.7 | 83 | female | 1 | 22 | 6.1 | 1 | alectinib 600 mg BID | 19.2 | false | MSS | 2026-03-15T05:36:01.428347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731066 | REC_0015766 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 15.7 | 60 | female | 0 | 16 | 4.7 | 5 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:01.428717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335477 | REC_0015767 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.8 | 56 | male | 0 | 18 | 4.8 | 4 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:36:01.429197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738554 | REC_0015768 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 1.5 | 71 | male | 3 | 9 | 5.3 | 2 | pembrolizumab 200 mg q3w | 26.3 | false | MSS | 2026-03-15T05:36:01.429650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997549 | REC_0015769 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.6 | 76 | female | 1 | 16 | 4.2 | 8 | entrectinib 600 mg daily | 15.7 | true | MSS | 2026-03-15T05:36:01.430009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620076 | REC_0015770 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 15.4 | 59 | male | 0 | 21 | 6.7 | 2 | alectinib 600 mg BID | 13.5 | false | MSI-H | 2026-03-15T05:36:01.430579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892831 | REC_0015771 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 10 | 57 | male | 1 | 8 | 5.6 | 6 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:36:01.431019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562945 | REC_0015772 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 20.7 | 65 | female | 1 | 17 | 6.5 | 6 | osimertinib 80 mg daily | 12.9 | true | MSS | 2026-03-15T05:36:01.431437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846206 | REC_0015773 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 9 | 59 | male | 0 | 16 | 6.7 | 6 | entrectinib 600 mg daily | 9.4 | true | MSS | 2026-03-15T05:36:01.431829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247361 | REC_0015774 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 15.6 | 60 | female | 0 | 8 | 6.8 | 2 | sotorasib 960 mg daily | 27.6 | false | MSI-H | 2026-03-15T05:36:01.432343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105311 | REC_0015775 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.8 | 70 | female | 2 | 11 | 5.2 | 5 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:36:01.432798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185143 | REC_0015776 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.7 | 56 | male | 0 | 10 | 4.3 | 9 | entrectinib 600 mg daily | 7.3 | false | MSS | 2026-03-15T05:36:01.433244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285060 | REC_0015777 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.4 | 61 | female | 0 | 15 | 5.5 | 5 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:36:01.433689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228320 | REC_0015778 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.8 | 73 | female | 2 | 14 | 5 | 6 | sotorasib 960 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:01.434106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833558 | REC_0015779 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.3 | 60 | male | 1 | 8 | 5.8 | 5 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:36:01.434523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242477 | REC_0015780 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.2 | 62 | female | 0 | 22 | 4.8 | 4 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:36:01.434921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547099 | REC_0015781 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.1 | 57 | male | 0 | 87 | 6.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:36:01.435292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326701 | REC_0015782 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14.4 | 69 | female | 0 | 8 | 4.7 | 7 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:01.435669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609076 | REC_0015783 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.1 | 80 | male | 1 | 19 | 7.2 | 2 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:01.436387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743298 | REC_0015784 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 12.7 | 64 | male | 0 | 19 | 6.3 | 0 | osimertinib 80 mg daily | 50.4 | true | MSS | 2026-03-15T05:36:01.436835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458408 | REC_0015785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.4 | 58 | female | 0 | 4 | 5.2 | 7 | alectinib 600 mg BID | 10.7 | true | MSI-H | 2026-03-15T05:36:01.437245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209497 | REC_0015786 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 17.7 | 59 | female | 1 | 10 | 5.2 | 2 | entrectinib 600 mg daily | 20.7 | true | MSS | 2026-03-15T05:36:01.437632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576769 | REC_0015787 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 7.1 | 50 | male | 0 | 28 | 5 | 4 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:01.438015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446495 | REC_0015788 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 6.3 | 66 | female | 0 | 30 | 3.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 39.2 | false | MSS | 2026-03-15T05:36:01.438398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818108 | REC_0015789 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 7 | 66 | female | 1 | 26 | 3.4 | 2 | alectinib 600 mg BID | 16.4 | false | MSS | 2026-03-15T05:36:01.438754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667070 | REC_0015790 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 8.2 | 68 | female | 0 | 22 | 5 | 4 | pembrolizumab 200 mg q3w | 16 | false | MSS | 2026-03-15T05:36:01.439134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806712 | REC_0015791 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 10 | 74 | female | 2 | 48 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSI-H | 2026-03-15T05:36:01.439525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859353 | REC_0015792 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.4 | 53 | female | 0 | 13 | 5.8 | 3 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:01.439885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385490 | REC_0015793 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.3 | 55 | female | 0 | 11 | 7 | 5 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:36:01.440324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730626 | REC_0015794 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9 | 76 | female | 2 | 11 | 5.3 | 2 | alectinib 600 mg BID | 15.4 | false | MSS | 2026-03-15T05:36:01.440713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679220 | REC_0015795 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 16.9 | 77 | female | 1 | 13 | 6.8 | 6 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:36:01.441100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778668 | REC_0015796 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.6 | 75 | female | 1 | 17 | 3.7 | 8 | pembrolizumab 200 mg q3w | 4.2 | true | MSS | 2026-03-15T05:36:01.441640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918359 | REC_0015797 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14 | 76 | female | 2 | 19 | 5.4 | 6 | sotorasib 960 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.442080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915360 | REC_0015798 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.3 | 73 | female | 3 | 22 | 6.8 | 5 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:36:01.442482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242162 | REC_0015799 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.4 | 68 | female | 0 | 38 | 5.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSS | 2026-03-15T05:36:01.442877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849935 | REC_0015800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7.5 | 76 | female | 1 | 27 | 5.2 | 4 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.443270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.